← All trials
NCT06161974
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2024
- Primary completion
- Jun 15, 2029
- Completion date
- Jun 15, 2035
- First posted
- Dec 8, 2023
- Last posted
- Dec 8, 2023
- Enrollment
- 65
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rigel PharmaceuticalsLead sponsor
- Ohio State UniversityLead sponsor
- University of PennsylvaniaStudy chair
- Rigel PharmaceuticalsCollaborator
- University of PennsylvaniaOfficial
- Ohio State UniversityOfficial
- Ohio State UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.